DMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products from USWM, LLC (?USWM? or ?US WorldMeds?). US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI and ZIMHI (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts.

The Company is now actively seeking out-license opportunities for SYMJEPI in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.